Aikium

Executive Summary

Aikium is a Boston-based private biotechnology company founded in 2020 that leverages artificial intelligence and machine learning to tackle one of the most challenging problems in drug discovery: targeting the 'undruggable' proteome. Nearly half of the human proteome consists of proteins with intrinsically disordered regions (IDRs) that are not adequately captured by current structure-based models, which are trained on only a fraction of available data. Aikium's platform aims to address this gap by applying advanced AI algorithms to model and predict the behavior of disordered proteins, thereby unlocking new therapeutic targets for a wide range of diseases. The company operates at the intersection of AI/ML and drug delivery, suggesting a focus on both target identification and enabling technologies to deliver therapeutics to these novel targets. As a private, early-stage company with no disclosed funding or valuation, Aikium is likely in the research or seed stage, building its proprietary platform and validating its approach. The biopharmaceutical industry has shown increasing interest in targeting intrinsically disordered proteins, and Aikium's position in Boston—a major biotech hub—may provide access to talent and partnerships. While the company has not yet published data or announced collaborations, its focus on a critical unmet need in drug discovery positions it for potential growth if its platform yields promising results. Key risks include the technical difficulty of modeling IDRs and the company's early stage of development.

Upcoming Catalysts (preview)

• 2026Series A Funding Announcement60% success
• 2027Preclinical Proof-of-Concept Data Release40% success
• 2026Academic or Industry Partnership50% success